Literature DB >> 10771089

Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after gamma-irradiation by stabilization of the protein.

K Fukuchi1, H Watanabe, S Tomoyasu, S Ichimura, K Tatsumi, K Gomi.   

Abstract

Expression of the cyclin kinase inhibitor, p21, is regulated both transcriptionally and posttranscriptionally by the ubiquitin-proteasome degradation pathway. Recently, we reported that DNA damage is required for efficient p21 expression by demonstrating that enhanced p21 mRNA expression induced by DNA damage results in increased p21 protein, but enhanced p21 mRNA without DNA damage does not. In addition, we demonstrated that DNA damage suppressed the ubiquitination of p21. In this study, we analyze the link between p21 stabilization and DNA damage. Enhanced p21 protein expression in ML-1 cells resulting from 15 Gy gamma-irradiation was diminished by Wortmannin or LY294002 pretreatment of cells. However, the levels of p21 mRNA were not affected by inhibitor pretreatment. Wortmannin or LY294002 pretreatment reduces p53 expression after gamma-irradiation to a lesser degree than that of p21. In addition, we examined the involvement of DNA-PK, whose activity is inhibited by Wortmannin or LY294002, in p21 stabilization using the SCID fibroblast cell line and a DNA-PK targeting ML-1 cell line. Accumulation of p21 protein by gamma-irradiation was similar to that of DNA-PK intact cells and was reduced by Wortmannin or LY294002 pretreatment. Involvement of another DNA damage detecting enzyme, the ATM gene product, whose activity is also inhibited by Wortmannin or LY294002, was evaluated. ATM deficient cells induced p21 after gamma-irradiation, gamma-irradiation-induced p21 protein was diminished by pretreatment of cells with Wortmannin or LY294002. We conclude that the p21 stabilization mechanism functions after gamma-irradiation, was sensitive to Wortmannin or LY294002, and required neither DNA-PK nor ATM gene product for activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10771089     DOI: 10.1016/s0167-4889(00)00018-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Authors:  Yintao Ye; Wenqing Xu; Wei Zhong; Yajing Li; Chen Wang
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

2.  Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells.

Authors:  L Rössig; A S Jadidi; C Urbich; C Badorff; A M Zeiher; S Dimmeler
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Redox regulation of interleukin-4 signaling.

Authors:  Pankaj Sharma; Rikhia Chakraborty; Lu Wang; Booki Min; Michel L Tremblay; Tsukasa Kawahara; J David Lambeth; S Jaharul Haque
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

4.  PI 3-K signaling pathway suppresses PMA-induced expression of p21WAF1/Cip1 in human leukemia cells.

Authors:  Augustas Pivoriūnas; Jūrate Savickiene; Grazina Treigyte; Virginijus Tunaitis; Rūta Navakauskiene; Karl-Eric Magnusson
Journal:  Mol Cell Biochem       Date:  2007-02-08       Impact factor: 3.396

5.  Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells.

Authors:  Wafica Itani; Fady Geara; Joelle Haykal; Makhluf Haddadin; Hala Gali-Muhtasib
Journal:  Radiat Oncol       Date:  2007-01-03       Impact factor: 3.481

6.  Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival.

Authors:  Ling Wang; Shamit K Dutta; Tatsuyoshi Kojima; Xiaolei Xu; Roya Khosravi-Far; Stephen C Ekker; Debabrata Mukhopadhyay
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

7.  Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Authors:  B P Nutley; N F Smith; A Hayes; L R Kelland; L Brunton; B T Golding; G C M Smith; N M B Martin; P Workman; F I Raynaud
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.